The effect of weekly risedronate on periprosthetic bone resorption following total hip arthroplasty: A randomized, double-blind, placebo-controlled trial

Journal of Bone and Joint Surgery

Volumn 93, Issue 20, 2011, Pages 1857-1864

  Sköldenberg, Olof Gustaf ^a   Salemyr, Mats Olof ^a   Bodén, Henrik Stefan ^a   Ahl, Torbjörn Efraim ^a   Adolphson, Per Yngve ^a  

^a DANDERYD HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM CARBONATE; PLACEBO; RISEDRONIC ACID; VITAMIN D;

ADULT; AGED; ARTICLE; BONE DENSITY; CLINICAL ARTICLE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; FEMUR FRACTURE; FOLLOW UP; HARRIS HIP SCORE; HIP DISLOCATION; HIP OSTEOARTHRITIS; HUMAN; MALE; NAUSEA; OSTEOLYSIS; PERIPROSTHETIC FRACTURE; POSTOPERATIVE PERIOD; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TOTAL HIP PROSTHESIS; TREATMENT DURATION; TREATMENT RESPONSE; URTICARIA;

EID: 80054871160     PISSN: 00219355     EISSN: 15351386     Source Type: Journal    
DOI: 10.2106/JBJS.J.01646     Document Type: Article

References (40)

1. Engh CA, Bobyn JD, Glassman AH. Porous-coated hip replacement. The factors governing bone ingrowth, stress shielding, and clinical results. J Bone Joint Surg Br. 1987;69:45-55. (Pubitemid 17098507)
2. Bobyn JD, Mortimer ES, Glassman AH, Engh CA, Miller JE, Brooks CE. Producing and avoiding stress shielding. Laboratory and clinical observations of noncemented total hip arthroplasty. Clin Orthop Relat Res. 1992;274:79-96.
3. Bobyn JD, Tanzer M, Glassman AH. Stress-related bone resorption. In: Shanbhag A; Rubash HE, Jacobs JJ, editors. Joint replacement and bone resorption: pathology, biomaterials, and clinical practice. New York: Taylor & Francis; 2006. p 375-97.
4. Bodén HS, Sköldenberg OG, Salemyr MO, Lundberg HJ, Adolphson PY. Continuous bone loss around a tapered uncemented femoral stem: a long-term evaluation with DEXA. Acta Orthop. 2006;77:877-85.
5. Streit MR, Merle C, Clarius M, Aldinger PR. Late peri-prosthetic femoral fracture as a majormode of failure in uncemented primary hip replacement. J Bone Joint Surg Br. 2011;93:178-83.
6. Lindahl H. Epidemiology of periprosthetic femur fracture around a total hip arthroplasty. Injury. 2007;38:651-4. (Pubitemid 46726315)
7. Miller PD, Brown JP, Siris ES, Hoseyni MS, Axelrod DW, Bekker PJ. A randomized, double-blind comparison of risedronate and etidronate in the treatment of Paget's disease of bone. Paget's Risedronate/Etidronate Study Group. Am J Med. 1999; 106:513-20. (Pubitemid 29231101)
8. Roux C, Ravaud P, Cohen-Solal M, de Vernejoul MC, Guillemant S, Cherruau B, Delmas P, Dougados M, Amor B. Biologic, histologic and densitometric effects of oral risedronate on bone in patients with multiple myeloma. Bone. 1994;15:41-9. (Pubitemid 24107941)
9. Harris ST, Watts NB, Genant HK, McKeever CD, Hangartner T, Keller M, Chesnut CH 3rd, Brown J, Eriksen EF, Hoseyni MS, Axelrod DW, Miller PD. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. JAMA. 1999;282:1344-52. (Pubitemid 29483192)
10. McClung MR, Geusens P, Miller PD, Zippel H, Bensen WG, Roux C, Adami S, Fogelman I, Diamond T, Eastell R, Meunier PJ, Reginster JY; Hip Intervention Program Study Group. Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. N Engl J Med. 2001;344:333-40. (Pubitemid 32107641)
11. Altman DG, Schulz KF, Moher D, Egger M, Davidoff F, Elbourne D, Gøtzsche PC, Lang T; CONSORT GROUP (Consolidated Standards of Reporting Trials). The revised CONSORT statement for reporting randomized trials: explanation and elaboration. Ann Intern Med. 2001;134:663-94. (Pubitemid 32322245)
12. World Medical Association. Declaration of Helsinki - ethical principles for medical research involving human subjects. 2008. http://www.wma.net/en/ 30publications/10policies/b3/index.html.
13. Dorr LD, Faugere MC, Mackel AM, Gruen TA, Bognar B, Malluche HH. Structural and cellular assessment of bone quality of proximal femur. Bone. 1993;14:231-42. (Pubitemid 23175734)
14. Gruen TA, McNeice GM, Amstutz HC. "Modes of failure" of cemented stem-type femoral components: a radiographic analysis of loosening. Clin Orthop Relat Res. 1979;141:17-27. (Pubitemid 10233166)
15. World Health Organization. WHO scientific group on the assessment of osteoporosis at primary health care level. 2011. http://www.who.int/chp/topics/ Osteoporosis.pdf. Accessed 2011 Jan 24.
16. Biedermann R, Krismer M, Stöckl B, Mayrhofer P, Ornstein E, Franzén H. Accuracy of EBRA-FCA in the measurement of migration of femoral components of total hip replacement. Einzel-Bild-Röntgen-Analyse- femoral component analysis. J Bone Joint Surg Br. 1999;81:266-72. (Pubitemid 29327065)
17. Krismer M, Biedermann R, Stöckl B, Fischer M, Bauer R, Haid C. The prediction of failure of the stem in THR by measurement of early migration using EBRA-FCA. Einzel-Bild-Roentgen-Analyse-femoral component analysis. J Bone Joint Surg Br. 1999;81:273-80. (Pubitemid 29327066)
18. Engh CA, Massin P, Suthers KE. Roentgenographic assessment of the biologic fixation of porous-surfaced femoral components. Clin Orthop Relat Res. 1990;257: 107-28. (Pubitemid 20246731)
19. DeLee JG, Charnley J. Radiological demarcation of cemented sockets in total hip replacement. Clin Orthop Relat Res. 1976;121:20-32. (Pubitemid 8003188)
20. Brooker AF, Bowerman JW, Robinson RA, Riley LH Jr. Ectopic ossification following total hip replacement. Incidence and a method of classification. J Bone Joint Surg Am. 1973;55:1629-32.
21. Harris WH. Traumatic arthritis of the hip after dislocation and acetabular fractures: treatment by mold arthroplasty. An end-result study using a new method of result evaluation. J Bone Joint Surg Am. 1969;51:737-55.
22. Rabin R, de Charro F. EQ-5D: a measure of health status from the EuroQol Group. Ann Med. 2001;33:337-43. (Pubitemid 32675374)
23. Downie WW, Leatham PA, Rhind VM, Wright V, Branco JA, Anderson JA. Studies with pain rating scales. Ann Rheum Dis. 1978;37:378-81. (Pubitemid 9017965)
24. Sköldenberg OG, Bodén HS, Salemyr MO, Ahl TE, Adolphson PY. Periprosthetic proximal bone loss after uncemented hip arthroplasty is related to stem size: DXA measurements in 138 patients followed for 2-7 years. Acta Orthop. 2006;77:386-92.
25. Alm JJ, Mäkinen TJ, Lankinen P, Moritz N, Vahlberg T, Aro HT. Female patients with low systemic BMD are prone to bone loss in Gruen zone 7 after cementless total hip arthroplasty. Acta Orthop. 2009;80:531-7.
26. Rahmy AI, Gosens T, Blake GM, Tonino A, Fogelman I. Periprosthetic bone remodelling of two types of uncemented femoral implant with proximal hydroxyapatite coating: a 3-year follow-up study addressing the influence of prosthesis design and preoperative bone density on periprosthetic bone loss. Osteoporos Int. 2004; 15:281-9. (Pubitemid 38543946)
27. Arabmotlagh M, Pilz M, Warzecha J, Rauschmann M. Changes of femoral periprosthetic bone mineral density 6 years after treatment with alendronate following total hip arthroplasty. J Orthop Res. 2009;27:183-8.
28. Venesmaa PK, Kröger HP, Miettinen HJ, Jurvelin JS, Suomalainen OT, Alhav EM. Alendronate reduces periprosthetic bone loss after uncemented primary total hip arthroplasty: a prospective randomized study. J Bone Miner Res. 2001;16:2126-31. (Pubitemid 32995405)
29. Wilkinson JM, Eagleton AC, Stockley I, Peel NF, Hamer AJ, Eastell R. Effect of pamidronate on bone turnover and implant migration after total hip arthroplasty: a randomized trial. J Orthop Res. 2005;23:1-8. (Pubitemid 40045070)
30. Wilkinson JM, Stockley I, Peel NF, Hamer AJ, Elson RA, Barrington NA, Eastell R. Effect of pamidronate in preventing local bone loss after total hip arthroplasty: a randomized, double-blind, controlled trial. J Bone Miner Res. 2001;16:556-64. (Pubitemid 32173371)
31. Yamasaki S, Masuhara K, Yamaguchi K, Nakai T, Fuji T, Seino Y. Risedronate reduces postoperative bone resorption after cementless total hip arthroplasty. Osteoporos Int. 2007;18:1009-15. (Pubitemid 46889560)
32. Friedl G, Radl R, Stihsen C, Rehak P, Aigner R, Windhager R. The effect of a single infusion of zoledronic acid on early implant migration in total hip arthroplasty. A randomized, double-blind, controlled trial. J Bone Joint Surg Am. 2009;91:274-81.
33. Hilding M, Ryd L, Toksvig-Larsen S, Aspenberg P. Clodronate prevents prosthetic migration: a randomized radiostereometric study of 50 total knee patients. Acta Orthop Scand. 2000;71:553-7.
34. Kärrholm J, Borssén B, Löwenhielm G, Snorrason F. Does early micromotion of femoral stem prostheses matter? 4-7-year stereoradiographic follow-up of 84 cemented prostheses. J Bone Joint Surg Br. 1994;76:912-7. (Pubitemid 24368446)
35. Thillemann TM, Pedersen AB, Mehnert F, Johnsen SP, Søballe K. Postoperative use of bisphosphonates and risk of revision after primary total hip arthroplasty: a nationwide population-based study. Bone. 2010;46:946-51.
36. Capeci CM, Tejwani NC. Bilateral low-energy simultaneous or sequential femoral fractures in patients on long-term alendronate therapy. J Bone Joint Surg Am. 2009;91:2556-61.
37. Rizzoli R, Akesson K, Bouxsein M, Kanis JA, Napoli N, Papapoulos S, Reginster JY, Cooper C. Subtrochanteric fractures after long-term treatment with bisphosphonates: a European Society on Clinical and Economic Aspects of Osteoporosis and Osteoarthritis, and International Osteoporosis Foundation Working Group Report. Osteoporos Int. 2011;22:373-90.
38. Nygaard M, Zerahn B, Bruce C, Søballe K, Borgwardt A. Early periprosthetic femoral bone remodelling using different bearing material combinations in total hip arthroplasties: a prospective randomised study. Eur Cell Mater. 2004;8:65-73.
39. Yamaguchi K, Masuhara K, Yamasaki S, Fuji T, Seino Y. Effects of discontinuation as well as intervention of cyclic therapy with etidronate on bone remodeling after cementless total hip arthroplasty. Bone. 2004;35:217-23. (Pubitemid 38789167)
40. Yamaguchi K, Masuhara K, Yamasaki S, Nakai T, Fuji T. Cyclic therapy with etidronate has a therapeutic effect against local osteoporosis after cementless total hip arthroplasty. Bone. 2003;33:144-9. (Pubitemid 36952696)